Waldenstrom's Macroglobulinemia
GPTKB entity
Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
plasma cells
|
| gptkbp:associated_with |
gptkb:lymphoplasmacytic_lymphoma
|
| gptkbp:clinical_trial |
dizziness
nausea abdominal pain fever vomiting joint pain shortness of breath headaches skin infections skin rashes hypercalcemia lymphadenopathy visual disturbances cognitive changes hepatomegaly splenomegaly oral ulcers |
| gptkbp:complications |
gptkb:fandom
infections thrombocytopenia neuropathy hyperviscosity syndrome |
| gptkbp:current_use |
gptkb:healthcare_organization
gptkb:non-Hodgkin_lymphoma |
| gptkbp:end_of_life |
5-year survival rate is around 70-80%.
|
| gptkbp:first_described_by |
gptkb:1944
|
| https://www.w3.org/2000/01/rdf-schema#label |
Waldenstrom's Macroglobulinemia
|
| gptkbp:is_characterized_by |
high levels of Ig M
|
| gptkbp:is_often_used_in |
older adults
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:named_after |
gptkb:Jan_Waldenström
|
| gptkbp:research_focus |
biomarkers
clinical trials genetic mutations treatment outcomes |
| gptkbp:risk_factor |
autoimmune diseases
family history exposure to certain chemicals |
| gptkbp:social_responsibility |
CT scan
variable bone marrow biopsy PET scan immunofixation electrophoresis serum protein electrophoresis |
| gptkbp:symptoms |
fatigue
weight loss night sweats bleeding problems |
| gptkbp:treatment |
gptkb:venetoclax
gptkb:ibrutinib gptkb:bendamustine gptkb:vaccine gptkb:rituximab chemotherapy targeted therapy plasma exchange stem cell transplant |
| gptkbp:bfsParent |
gptkb:Bing_Center_for_Waldenstrom's_Macroglobulinemia
|
| gptkbp:bfsLayer |
7
|